Finanzen von Compass Therapeutics Inc. (CMPX)CMPXCompass Therapeutics Inc.

Evaluating the bottom line, Compass Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -56.66%, provide a clear picture of how effectively CMPX converts its operational activities into shareholder value.

In the context of the broader market, CMPX competes directly with industry leaders such as ARCT and AVIR. With a market capitalization of $405.20M, it holds a significant position in the sector. When comparing efficiency, CMPX's gross margin of N/A stands against ARCT's 100.00% and AVIR's N/A. Such benchmarking helps identify whether Compass Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

The company has reported consistent losses, with a net income of -25,154,000 USD in Q2 2026 and a gross margin of 0% in recent quarters, reflecting financial struggles.